Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q1 2026 · 10-Q
Revenue$127.20M$127.20M+55.6% vs Q1 2025 Net Income-$37.10M-$37.10MN/M vs Q1 2025 EPS Diluted-$0.40-$0.40N/M vs Q1 2025 Operating Income-$36,915,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
Margins · derivedOperating margin-29.0%+23.2 pt vs Q1 2025
Net margin-29.2%+21.3 pt vs Q1 2025
ended Mar 31, 2026 · filed May 4, 2026 · 34 d after period end